



P H Y S I C A L S C I E N C E S I N C .

October 13, 2006

Mr. Edward Hammond
The Sunshine Project
P.O. Box 41987
Austin, TX 78704

Dear Mr. Hammond:

Your original message was never received by the IBC. In the future please address communications to "Institutional Biosafety Committee Chair" to ensure that it is received. I have attached the requested minutes to this letter.

PSI initiated NIH-funded rDNA activities May, 2005. At that time, our IBC was activated and registered with the NIH. PSI has only two programs involving minimal use of rDNA. One involves the development of a cell line to model bone loss in astronauts. The other involves the development of a model for neurodegeneration in the nematode *Caenorhabditis elegans*. No significant concerns regarding these programs were expressed by the members of the IBC.

Do not hesitate to contact me directly if you have any questions.

Sincerely,

A handwritten signature in blue ink that reads "Anthony Ferrante". The signature is fluid and cursive, with the first name being more prominent.

Anthony Ferrante, PhD
Chair, Institutional Biosafety Committee

Minutes of rDNA Meeting

Attendees: Anthony Ferrante, Amy Bauer, Daniel Hammer

Topic: Review of PSI rDNA activities

Date: October 31, 2005

Discussion centered on two currently active PSI programs that involve the use of recombinant DNA. Current activity on PSI contract 2870, "Protein localization in living cells", was discussed. Current activities are following the IBC approved experimental safety plan.

PSI contract 1467 was recently initiated. There was brief discussion of the proposed rDNA activities. Those activities are covered under the PSI project registration for PSI IRAD 9021. There were no concerns regarding the proposed research.

Minutes of rDNA Meeting

Attendees: Anthony Ferrante, Amy Bauer, Daniel Hammer, Chad Bigelow

Topic: Review of PSI rDNA activities

Date: March 17, 2006

Discussion centered on two currently active PSI programs that involve the use of recombinant DNA. Current activity on PSI contract 2870, "Protein localization in living cells", was discussed. Current activities are following the IBC approved experimental safety plan.

Current activity on PSI contract 1467, "Multiplexed Drug Discovery Assay for Neurodegeneration" was discussed. Current activities are following the IBC approved experimental safety plan. There were no concerns expressed regarding either program.

There was brief discussion on our continued inability to convince the Chair of the Andover Board of Health to attend the IBC meetings. The Chair recently retired. Anthony Ferrante will contact the new Chair to update him on current PSI rDNA activities.

Minutes of rDNA Meeting

Attendees: Anthony Ferrante, Amy Bauer, Daniel Hammer, Chad Bigelow

Topic: Review of PSI rDNA activities

Date: September 26, 2006

Discussion centered on two currently active PSI programs that involve the use of recombinant DNA. Current activity on PSI contract 2870, "Protein localization in living cells", was discussed. The molecular biology portion of this work has ended. Final experiments involve collection of images of cell lines that express fluorescent proteins.

Current activity on PSI contract 1467, "Multiplexed Drug Discovery Assay for Neurodegeneration" was discussed. The molecular biology activities for this program have recently ended. Remaining activity involves injection of rDNA into *C. elegans* for use in imaging studies. There were no concerns expressed regarding either program.